The estimated Net Worth of Michael Thomas Heffernan is at least $20.4 Million dollars as of 22 December 2022. Mr. Heffernan owns over 25,041 units of Collegium Pharmaceutical Inc stock worth over $1,152,717 and over the last 16 years he sold COLL stock worth over $19,001,995. In addition, he makes $250,984 as Chairman of the Board at Collegium Pharmaceutical Inc.
Michael has made over 28 trades of the Collegium Pharmaceutical Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 25,041 units of COLL stock worth $404,412 on 22 December 2022.
The largest trade he's ever made was selling 295,287 units of Collegium Pharmaceutical Inc stock on 21 January 2020 worth over $6,475,644. On average, Michael trades about 14,985 units every 29 days since 2008. As of 22 December 2022 he still owns at least 31,843 units of Collegium Pharmaceutical Inc stock.
You can see the complete history of Mr. Heffernan stock trades at the bottom of the page.
Michael Thomas Heffernan serves as Chairman of the Board of the Company. Mr. Heffernan has served as a member of our board of directors since October 2003 and served as our President and Chief Executive Officer from October 2003 to June 2018. Since then, Mr. Heffernan has served as a consultant to pharmaceutical and biotechnology companies. Mr. Heffernan has over twenty-five years of experience in the pharmaceutical and related healthcare industries. He was previously the Founder, President and Chief Executive Officer of Onset Therapeutics, LLC, a dermatology-focused company that developed and commercialized products for the treatment of skin-related illnesses and was responsible for the spin-off of the business from the Company to create PreCision Dermatology, Inc. which was acquired by Valeant Pharmaceuticals International, Inc. Mr. Heffernan has held prior positions as Co-Founder, President and Chief Executive Officer of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp., and as President and Chief Executive Officer of PhyMatrix. Mr. Heffernan started his career at Eli Lilly and Company, where he served in numerous sales and marketing roles. Mr. Heffernan serves on the board of directors of Akebia Therapeutics, Inc. (NASDAQ: AKBA) (December 2018 to present), Trevi Therapeutics, Inc. (NASDAQ: TRVI) (2017 to present) and Biohaven Pharmaceutical Holding Company Ltd. (NSYE: BHVN) (January 2020 to present). Mr. Heffernan previously served on the board of directors of Keryx Biopharmaceuticals, Inc., a public pharmaceutical company prior to its merger with Akebia, Ocata Therapeutics, Inc. (NASDAQ: OCAT), Cornerstone Therapeutics Inc. (now known as Chiesi USA, Inc.) (NASDAQ: CRTX), and Veloxis Pharmaceuticals A/S, prior to its acquisition by Asahi Kasei. Mr. Heffernan is a current member of the boards of several privately held companies. Mr. Heffernan graduated from the University of Connecticut with a B.S. in Pharmacy in 1987 and is a Registered Pharmacist.
As the Chairman of the Board of Collegium Pharmaceutical Inc, the total compensation of Michael Heffernan at Collegium Pharmaceutical Inc is $250,984. There are 9 executives at Collegium Pharmaceutical Inc getting paid more, with Joseph Ciaffoni having the highest compensation of $4,032,630.
Michael Heffernan is 55, he's been the Chairman of the Board of Collegium Pharmaceutical Inc since 2018. There are 11 older and 8 younger executives at Collegium Pharmaceutical Inc. The oldest executive at Collegium Pharmaceutical Inc is John Fallon, 72, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510.
Over the last 10 years, insiders at Collegium Pharmaceutical Inc have traded over $80,399,308 worth of Collegium Pharmaceutical Inc stock and bought 1,112,375 units worth $13,316,951 . The most active insiders traders include Group Holdings (Sbs) Adviso..., John Gordon Freund und David Hirsch. On average, Collegium Pharmaceutical Inc executives and independent directors trade stock every 35 days with the average trade being worth of $2,130,406. The most recent stock trade was executed by Shirley R. Kuhlmann on 5 September 2024, trading 20,225 units of COLL stock currently worth $773,809.
collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex
Collegium Pharmaceutical Inc executives and other stock owners filed with the SEC include: